Nestle to invest in Aimmune Therapeutics for $2.6 billion
Nestle plans to shell out $2 billion to obtain whole ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss...
Nestle plans to shell out $2 billion to obtain whole ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss...